CA-PROSIMO
30.11.2022 15:02:07 CET | Business Wire | Press release
Prosimo, the Application Experience Infrastructure company, announced that it is joining forces with Amazon Web Services (AWS) to provide complete end-to-end orchestration for the new AWS Verified Access service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005237/en/
Prosimo is joining forces with Amazon Web Services (AWS) to provide complete end-to-end orchestration for the new AWS Verified Access service (Graphic: Business Wire)
Prosimo is working with AWS to allow enterprises to customize and deploy zero trust network access (ZTNA) rapidly while ensuring complete data and traffic control. Prosimo's platform simplifies the orchestration of the AWS Verified Access service and provides additional performance optimization using AWS backbone, intelligent routing, and application services. Enterprises can instantaneously access any of the latest cloud-native capabilities, like AWS Verified Access, without having to re-architect their existing clouds or worry about managing multiple environments. This approach enables enterprises to quickly develop, test and deploy secure, high-performing applications across any public or hybrid cloud environment.
"Cloud-forward organizations require a cloud-native ZTNA architecture - one that combines secure access with performance and posture to meet the challenges of modern applications in the cloud," said Ramesh Prabagaran, Co-founder and CEO of Prosimo. "Our deepening work with AWS allows us to deliver tightly coupled integrations rapidly that enable customers to simplify and streamline IT operations with fewer resources."
Why traditional ZTNA solutions fall short
Traditional ZTNA approaches take traffic to the vendor cloud-first to enforce policies and bring it back to the AWS Region close to the application. The model breaks a well-architected framework by not utilizing cloud-native services and optimized flows using AWS backbone and services such as AWS Transit Gateway, AWS Cloud WAN, AWS Global Accelerator, and AWS PrivateLink. This often leads to operational complexity, increasing risk, escalating costs, and negative impacts on performance.
Secure Access + Performance at Cloud Speed
Prosimo provides an end-to-end orchestration solution with advanced controls using these cloud-native services from AWS. The Prosimo Full Stack takes a comprehensive approach to help customers deploy AWS Verified Access and includes performance optimization, secure access, dynamic risk calculation, and orchestration of all ecosystem components, such as identity provider [IDP] integration, Domain Name Service [DNS], and connectivity, without any traffic leaving customers’ AWS environment. In addition to secure access, Prosimo can balance and optimize performance and costs per application basis.
One-click purchase and billing in AWS Marketplace
Prosimo solutions are available in AWS Marketplace and allow customers to seamlessly consume Prosimo solutions with one easy click of a button and consolidate billing.
Resources
- 2022 Gartner® Market Guide for Multicloud Networking Software
- Turbo Charge ZTNA with Prosimo and AWS [Technical Blog]
- AWS + Prosimo
- Prosimo Full Stack Cloud Transit
- Prosimo + AWS Cloud WAN
- Cloud Field Day: Simplifying Multi-Cloud Networking with Prosimo
Connect with Prosimo
About Prosimo
Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Strengthens European Operations Through Compliance, Local Manufacturing, and Regional Services2.7.2026 08:30:00 CEST | Press release
The Smarter E Europe 2026 opened in Munich on June 23 and runs through June 25, gathering global players from the clean energy sector on one of Europe’s most influential trade exhibition platforms. EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, all-scenario storage solutions, and high-performance EV batteries — showcasing its lithium-sodium dual-technology platform, full product portfolio, and localized European operational layout. During the exhibition, European clients showed strong interest in the company’s product performance and placed strong emphasis on sustained adherence to the EU’s evolving regulatory standards. This industry attitude further underscores that regulatory compliance readiness has become a fundamental prerequisite for accessing the European clean energy market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701651416/en/ The BMW iX3 displayed at the EVE Energy booth
Braun Launches the Next Generation of Electric Shaver With Braun NEVO Introducing a New Dawn of Smooth Touch2.7.2026 08:00:00 CEST | Press release
With over 100 years of exceptional German craftsmanship, Braun introduces Braun NEVO, an electric shaver redefining what a close shave and smooth skin mean. Every element has been reimagined: the sleek unibody stainless steel handle, the revolutionary AeroTouch™ Technology and advanced personalized display deliver a perfectly close shave without sacrificing comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701842080/en/ Braun NEVO Shaver Oliver Grabes, Braun Head of Design, said: “At Braun, we set out to reimagine the shaving experience which led to the development of AeroTouch™ Shaving Technology, a cutting system engineered for ultra-low friction on the skin and high efficiency. This makes Braun NEVO our best shaver* setting a new standard for smooth skin.” Introducing the revolutionary world’s first AeroTouch™ Technology, featuring 250 diamond-sharp cutting edges and an exclusive Ultra gliding foil for a smooth g
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member2.7.2026 08:00:00 CEST | Press release
Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will remain an active board member. Eric brings extensive experience in healthcare innovation and value creation, having notably led BIOCORP through its development and acquisition by Novo Nordisk. Brenus also appoints Camilla SYLVEST, as a second independent director, following the earlier addition of Diala EZZEDDINE a seasoned US-based biotech executive and entrepreneur. Camilla SYLVEST is an experienced pharmaceutical executive and global business leader, having spent nearly three decades at Novo Nordisk A/S, where she most recently served as Executive Vice President for Global Commercial Strategy, Corporate Communication and Sustainability. She currently serves on the Boards of Argenx SE, Getinge AB, and Zealand Pharma A/S, and has previously served on the Board of Danish Crown A/S and as
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom